HOOKIPA Pharma Inc. (HOOK)

US — Healthcare Sector
Peers: MREO  TERN  PDSB  INZY  DAWN  ELDN  XFOR  ABOS  AMLX 

Automate Your Wheel Strategy on HOOK

With Tiblio's Option Bot, you can configure your own wheel strategy including HOOK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol HOOK
  • Rev/Share 0.6095
  • Book/Share 2.8272
  • PB 0.5695
  • Debt/Equity 0.0175
  • CurrentRatio 3.6119
  • ROIC -1.7876

 

  • MktCap 19624514.0
  • FreeCF/Share -4.3857
  • PFCF -0.3712
  • PE -0.2647
  • Debt/Assets 0.0097
  • DivYield 0
  • ROE -1.206

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade HOOK RBC Capital Mkts Outperform Sector Perform $48 $2 Dec. 20, 2024

News

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
HOOK
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

Read More
image for news HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

About HOOKIPA Pharma Inc. (HOOK)

  • IPO Date 2019-04-18
  • Website https://www.hookipapharma.com
  • Industry Biotechnology
  • CEO Dr. Malte Peters M.D.
  • Employees 82
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.